Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
To evaluate the effect of cysteamine treatment on the ability of bone marrow stromal cells to support osteoclast differentiation, we isolated bone marrow cells from long bones of WT and KO mice and cultured them in the presence of Vitamin D3.
Source: Cysteamine treatment affects ctns-/: osteoblasts in vitro and in vivo. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Moreover, we demonstrated that Pepstatin A treatment increased bone formation in vitro acting on the Fibronectin/Sipa1/STAT3/JunB pathway, and rescued somatic growth and bone mass in pre-pubertal ctns-/: mice.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
From Cysteamine to Pepstatin A: Targeting Cathepsin D To Improve Bone Health in Cystinosis
Study design awaiting verification · International Journal of Biological Sciences · 2026
Original publication title
From Cysteamine to Pepstatin A: Targeting Cathepsin D To Improve Bone Health in Cystinosis
© The author(s)
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Nephropathic cystinosis is a rare genetic lysosomal storage disorder caused by loss-of-function variants of the CTNS gene encoding for the lysosomal H+/cystine symporter cystinosin. The lack of cystinosin causes cystine accumulation in lysosomes and cell damage. Children with nephropathic cystinosis commonly exhibit skeletal abnormalities, including growth retardation, osteopenia and rickets. The only cystine-depleting drug available is cysteamine. However, several observations suggest that cysteamine, particularly at high doses, may have negative effects on the skeleton. In this study, we characterized the effects of cysteamine on bone cells and we identified Pepstatin A, a Cathepsin D-inhibitor, as a potential new therapeutic treatment to restore physiological bone remodeling in cystinosis.
We observed a detrimental effect of cysteamine on bone cells inducing further impairment of osteoblast differentiation/activity and failure of cysteamine intraperitoneal injection to improve the somatic growth of pre-pubertal ctns-/- mice. Moreover, we demonstrated that Pepstatin A treatment increased bone formation in vitro acting on the Fibronectin/Sipa1/STAT3/JunB pathway, and rescued somatic growth and bone mass in pre-pubertal ctns-/- mice. Our results provide evidence that cysteamine negatively affects bone in cystinosis and that Cathepsin D inhibition could represent a new therapeutic approach for rescue of bone remodeling in cystinosis.
Authors’ abstract
Nephropathic cystinosis is a rare genetic lysosomal storage disorder caused by loss-of-function variants of the CTNS gene encoding for the lysosomal H+/cystine symporter cystinosin. The lack of cystinosin causes cystine accumulation in lysosomes and cell damage. Children with nephropathic cystinosis commonly exhibit skeletal abnormalities, including growth retardation, osteopenia and rickets. The only cystine-depleting drug available is cysteamine. However, several observations suggest that cysteamine, particularly at high doses, may have negative effects on the skeleton. In this study, we characterized the effects of cysteamine on bone cells and we identified Pepstatin A, a Cathepsin D-inhibitor, as a potential new therapeutic treatment to restore physiological bone remodeling in cystinosis.
We observed a detrimental effect of cysteamine on bone cells inducing further impairment of osteoblast differentiation/activity and failure of cysteamine intraperitoneal injection to improve the somatic growth of pre-pubertal ctns-/- mice. Moreover, we demonstrated that Pepstatin A treatment increased bone formation in vitro acting on the Fibronectin/Sipa1/STAT3/JunB pathway, and rescued somatic growth and bone mass in pre-pubertal ctns-/- mice. Our results provide evidence that cysteamine negatively affects bone in cystinosis and that Cathepsin D inhibition could represent a new therapeutic approach for rescue of bone remodeling in cystinosis.
Publication and source details
Original title: From Cysteamine to Pepstatin A: Targeting Cathepsin D To Improve Bone Health in Cystinosis
Giulia Battafarano; Michela Rossi; Olivia Pagliarosi; Laura Di Giuseppe; Jacopo Di Gregorio; Sara Terreri; Cristiano De Stefanis; Marco Pezzullo; Gianna Di Giovamberardino; Pamela Vernocchi; Valeria Marzano; Lorenza Putignani; Jessica D'Amico; Fiorella Piemonte; Anna Taranta; Francesco Emma; Andrea Del Fattore
International Journal of Biological Sciences · 2026
✉ Corresponding author: Andrea Del Fattore, Head of the Bone Physiopathology Research Unit, Translational Pediatrics and Clinical Genetics Research Division, Bambino Gesù Children's Hospital, IRCCS, Viale San Paolo 15, 00146, Rome, Italy, Phone: +390668593740, Email: andrea.delfattore@opbg.netCompeting Interests: The authors have declared that no competing interest exists.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:56:09.429913+00:00
DOI: 10.7150/ijbs.135791 · PMC13540694